Experion Completes Second Sale to Emerald Health
Experion Completes Second Sale to Emerald Health
Vancouver, British Columbia (FSCwire) - Viridium Pacific Group Ltd. (“Viridium” or the “Company”) (TSXV: VIR) (OTCPink: VIRFF) is pleased to announce that its wholly owned subsidiary, Experion Biotechnologies Inc. (“Experion”), has completed its second sale of dried medical cannabis to Emerald Health Therapeutics Canada Inc. (“Emerald”) (TSXV: EMH), a Licensed Producer (“LP”) headquartered in Victoria, British Columbia. Emerald is one of Canada’s leading LPs, having attained its License to Produce in 2014, with cultivation and research facilities in British Columbia and Quebec. The sale follows closely on Experion’s first sale of dried medical cannabis (announced on October 1, 2017).
Mr. Jarrett Malnarich, Chief Executive Officer of Viridium, commented, "Our second customer, Emerald, represents a second vote of confidence in the product quality, safety, and production practices of Experion. We are very excited to be working with Emerald, a company with a longstanding reputation across Canada as a preeminent supplier to the medical market. With Emerald’s supply relationships for the adult use markets in BC, Ontario, and Newfoundland, we look forward to the potential for an expanded commercial relationship.”
About Viridium
Viridium Pacific Group Ltd. is a consumer wellness and biotech innovation company based in British Columbia, and the parent company of operating subsidiaries involved in horticultural production, (Experion Biotechologies Inc.) property development (Fish Trap Ventures Ltd.), and human resource management (Stave Lake Services Ltd.) Experion Biotechnologies Inc., is a Health Canada licensed producer of cannabis, which operates in an 8,300 square-foot indoor facility outside of Mission, BC.
More information about Viridium can be found under the Company's profile on SEDAR at www.sedar.com.
For further information:
Viridium Pacific Group Ltd.
Jarrett Malnarich
Tel: (604) 837-8688
Renmark Financial Communications Inc.
Melanie Barbeau: [email protected]
Tel: (416) 644-2020 or (514) 939-3989
Disclosure
This press release contains forward-looking information within the meaning of Canadian securities laws. Although the Company believes that such information is reasonable, it can give no assurance that such expectations will prove to be correct.
Forward looking information is typically identified by words such as: believe, expect, anticipate, intend, estimate, forecast, postulate and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking information provided by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking information as a result of various factors, including, but not limited to: the state of the financial markets for the Company's equity securities; recent market volatility; the Company's ability to raise the necessary capital or to be fully able to implement its business strategies; the risks identified in the Filing Statement, and other risks and factors that the Company is unaware of at this time. The reader is referred to the Filing Statement dated September 25, 2017 and/or the most recent annual and interim Management's Discussion and Analysis for a more complete discussion of such risk factors and their potential effects, copies of which may be accessed through the Company page on SEDAR at www.sedar.com.
To view the original release, please click here
Source: Viridium Pacific Group Ltd. (TSX Venture:VIR, OTC Pink:VIRFF)
To follow Viridium Pacific Group Ltd. on your favorite social media platform or financial websites, please click on the icons below.
Maximum News Dissemination by FSCwire. https://www.fscwire.com
Copyright © 2018 FSCwire
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
